S.B. Kim

1.3k total citations · 1 hit paper
12 papers, 501 citations indexed

About

S.B. Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, S.B. Kim has authored 12 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in S.B. Kim's work include Cancer Treatment and Pharmacology (4 papers), Breast Cancer Treatment Studies (3 papers) and Central Venous Catheters and Hemodialysis (2 papers). S.B. Kim is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Breast Cancer Treatment Studies (3 papers) and Central Venous Catheters and Hemodialysis (2 papers). S.B. Kim collaborates with scholars based in South Korea, United States and Japan. S.B. Kim's co-authors include Sherene Loi, Joohyuk Sohn, Y.H. Park, A. Wang, Konstantinos Tryfonidis, Lei Yin, Vassiliki Karantza, Roberto Salgado, Theodoros Foukakis and Peter Schmid and has published in prestigious journals such as Kidney International, Annals of Oncology and Heliyon.

In The Last Decade

S.B. Kim

12 papers receiving 491 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

2020 279 citations Peter Schmid, Roberto Salgado et al. Annals of Oncology profile →

Peers

S.B. Kim

ONCOL

PRM

IMMUN

CR

EMS

Ming‐Shian Lu Taiwan

N. Finkler United States

Luis Miguel Juárez‐Salcedo Spain

Wanli Liu China

Juan W Zinser Mexico

Gita Bhat Canada

P. Martin Romano France

L.T. Vlasveld Netherlands

Jianming Hu China

Kristy Watkins United States

Ming‐Shian Lu Taiwan

S.B. Kim

196 ×0.6

ONCOL

148 ×0.9

PRM

145 ×1.2

IMMUN

40 ×0.4

CR

69 ×0.8

EMS

Citations per year, relative to S.B. Kim S.B. Kim (= 1×) peers Ming‐Shian Lu

Countries citing papers authored by S.B. Kim

Since Specialization

Citations

This map shows the geographic impact of S.B. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.B. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.B. Kim more than expected).

Fields of papers citing papers by S.B. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.B. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.B. Kim. The network helps show where S.B. Kim may publish in the future.

Co-authorship network of co-authors of S.B. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of S.B. Kim. A scholar is included among the top collaborators of S.B. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.B. Kim. S.B. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Ohno, Shinji, S.B. Kim, Xuchen Cao, et al.. (2025). 291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). Annals of Oncology. 36. S302–S303. 1 indexed citations

2.

Kim, S.B., et al.. (2024). CD133-containing microvesicles promote colorectal cancer progression by inducing tumor angiogenesis. Heliyon. 10(7). e29292–e29292. 6 indexed citations

3.

Brufsky, Adam, S.B. Kim, Zanete Zvirbule, et al.. (2021). A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Annals of Oncology. 32(5). 652–660. 67 indexed citations

4.

Schmid, Peter, Roberto Salgado, Y.H. Park, et al.. (2020). Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology. 31(5). 569–581. 279 indexed citations breakdown →

5.

Saeki, Toshiaki, Hirofumi Mukai, Jungsil Ro, et al.. (2017). A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Annals of Oncology. 28. v80–v81. 7 indexed citations

6.

Im, S.-A., Hirofumi Mukai, Norikazu Masuda, et al.. (2016). 116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor-positive (ER +)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). Annals of Oncology. 27. ix35–ix35. 5 indexed citations

7.

Ryu, M.-H., Yubin Kang, Kwang Pyo Kim, et al.. (2016). Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer. Annals of Oncology. 27. vi234–vi234. 14 indexed citations

8.

Robinson, Bruce, Martin Schlumberger, Lori J. Wirth, et al.. (2016). Responses in specific metastases following treatment with lenvatinib (LN): Results from the phase 3 SELECT trial. Annals of Oncology. 27. vi332–vi332. 1 indexed citations

9.

Lee, Jun Young, et al.. (2010). Comparison of the Molecular Adsorbent Recirculating System and Plasmapheresis for Patients With Graft Dysfunction After Liver Transplantation. Transplantation Proceedings. 42(7). 2625–2630. 16 indexed citations

10.

Kim, Hwa Jung, et al.. (2009). Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea. European Journal of Surgical Oncology. 35(9). 936–941. 6 indexed citations

11.

Shin, Ji Hoon, et al.. (2008). Management of airway involvement of oesophageal cancer using covered retrievable nitinol stents. Clinical Radiology. 64(2). 133–141. 14 indexed citations

12.

Kim, Sung‐Han, et al.. (2005). Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: A prospective, randomized clinical trial. Kidney International. 69(1). 161–164. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact